Astra seeks U.S. okay for Seroquel XR in anxiety
LONDON, May 8 (Reuters) - AstraZeneca Plc (AZN.L: Quote, Profile, Research) said on Thursday it had applied to U.S. regulators to sell its schizophrenia drug Seroquel XR as a treatment for anxiety.
If approved, Seroquel XR would be the first atypical antipsychotic medicine cleared for the treatment of generalised anxiety disorder.
Seroquel XR -- a follow-on extended release version of AstraZeneca's older $4 billion-a-year seller Seroquel -- was approved in the United States for schizophrenia in 2007. AstraZeneca is also seeking clearance to sell the new drug for bipolar disorder. (Reporting by Ben Hirschler)
© Thomson Reuters 2008 All rights reserved
Help us advance this story. Provide relevant links or share your insights using our comment box. Please be considerate and help us by reporting any abuse you find. Reuters will delete comments that don't meet community standards.
Have a correction to this article? Email the editors
Sphere
Uneasy Truce
Kung Fu finger calls it a day
